

Studying the differential efficacy of post-symptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model

Amram Torgeman,^{a∞} Arie Schwartz,^{a∞} Eran Diamant,^a Tzadok Baruchi,^a Eyal Dor,^a Alon Ben David,^a Avi Pass,^a Ada Barnea,^a Arnon Tal,^a Amir Rosner,^b Osnat Rosen,^a Ran Zichel^{a#}

^aDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel; ^bThe Veterinary Center for Pre-clinical Research, Israel Institute for Biological Research, Ness Ziona, Israel

[#]Corresponding author; e-mail: ranz@iibr.gov.il (R. Zichel); Tel.: +972-8-9385873; Fax: +972-8-9381760

[∞]These authors contributed equally to this work.

Abstract

Botulinum neurotoxin (BoNT) serotypes A, B and E are responsible for most cases of human botulism. The only approved therapy for botulism is antitoxin treatment administered to patients after symptom onset. However, a recent meta-analysis of antitoxin efficacy in human botulism cases over the last century concluded that a statistically significant reduction in mortality is associated with the use of type-E and type-A but not type-B antitoxin. Animal models could be highly valuable in studying post-symptom antitoxin efficacy (PSAE). However, the only few attempts to evaluate PSAE in animals relied on subjective observations and showed approximately 50% protection. Recently, we developed a novel spirometry model for quantitative evaluation of PSAE in rabbits and used it to demonstrate full protection against BoNT/E. In the current study, comparative evaluation of PSAE in botulism types A and B was conducted using this quantitative respiratory model. A lethal dose of each toxin induced a comparable course of disease both in terms of time to symptoms (TTS, 41.9 ± 1.3 and 40.6 ± 1.1 h, respectively) and of time to death (TTD, 71.3 ± 3.1 and 66.3 ± 1.7 h, respectively). However, in accordance with the differential serotypic PSAE in human, post-symptom antitoxin treatment was fully effective only in BoNT/A-intoxicated rabbits. This serotypic divergence was reflected by a positive and statistically significant correlation between TTS and TTD in BoNT/A- ($r=0.91$, $P=0.0006$) but not in BoNT/B- ($r=0.06$, $P=0.88$) intoxicated rabbits. The rabbit spirometry system may be useful in the evaluation toolkit of botulism therapeutics, including those under development and intended to act when antitoxin is no longer effective.

Introduction

Botulinum neurotoxins (BoNTs) produced by the anaerobic bacterium *Clostridium botulinum* are the most potent toxins known in nature, with an estimated human lethal dose fifty (HLD₅₀) of 1 ng/kg of body weight (Arnon et al., 2001). BoNT serotypes A, B, E and rarely F are responsible for most cases of human botulism (Pirazzini et al., 2017). Following entry into circulation, BoNTs block acetylcholine transmission across neuromuscular junctions at pre-synaptic motor-neuron terminals and cause bilateral flaccid paralysis that eventually ends in respiratory failure (Dembek et al., 2007; Sugiyama, 1980). Wide-spread outbreaks of food-borne botulism might involve dozens of infected people that without adequate treatment may die (Kongsaengdao et al., 2006; McCarty et al., 2015; Weber et al., 1993), and thus, BoNTs pose a significant concern for health authorities. In addition, due to their extreme potency, BoNTs are classified as category A bio-threat agents (Centers for Disease Control and Prevention, <https://emergency.cdc.gov/agent/agentlist-category.asp>).

The only currently approved therapy for botulism is post-symptomatic administration of botulinum antitoxin, and in severe cases, intensive supportive care by means of mechanical ventilation. Antitoxin preparations are derived from equine plasma for adult patients (Centers for Disease Control and Prevention, 2010) or from human plasma in cases of infant botulism (<http://www.infantbotulism.org>). Botulinum antitoxin is expected to be useful mainly in neutralizing circulating BoNT molecules that are not yet bound to nerve endings (Sobel, 2005). Hence, prompt antitoxin treatment should slow the course of the disease and reduce pulmonary distress by preventing the toxin from binding to its target (Tacket et al., 1984). Indeed, data collected from observations in human clinical cases and from animal studies support the existence of a critical "therapeutic time window" for effective antitoxin treatment following botulinum intoxication (Tacket et al., 1984). Notably, antitoxin is given only to symptomatic patients due to the concern of potential adverse effects associated with its equine source and its immunogenic nature. Nevertheless, while antitoxin is administered to patients only after symptom onset, its efficacy evaluation in animal studies has been mostly related to time post-intoxication regardless of symptoms (Franz et al., 1993; Habermann and Bernath, 1975;

lida et al., 1970a; lida et al., 1970b; Lewis Jr and Metzger, 1979; Ono et al., 1969; Ono et al., 1970).

Recently, we established a novel quantitative and objective animal model for evaluation of post-symptom antitoxin efficacy (PSAE) that relies on spirometry detection of early respiratory symptoms of botulism in rabbits (Diamant et al., 2018). This model was used to demonstrate, for the first time, full protection of animals intoxicated with a lethal dose of BoNT/E, the fastest-acting of all BoNT serotypes.

In humans, BoNT/A and BoNT/B intoxications pose a greater threat than BoNT/E for several reasons. They are more potent, have a longer *in vivo* activity resulting in extended hospitalization time and, at least for BoNT/A, are more frequently associated with human botulism (Johnson and Montecucco, 2008; Rossetto et al., 2014). Importantly, a recent meta-analysis of antitoxin efficacy in human cases of food-borne botulism over the last century concluded that a statistically significant reduction in botulism-related mortality was associated with the use of type-E and type-A but not with type-B antitoxin (O'Horo et al., 2017). As the rabbit spirometry model was the first to produce comparable post-symptom treatment outcomes to those obtained in human patients, we sought to use this model in the current study to conduct a comparative evaluation of PSAE in type A and type B botulism. BoNT/A and BoNT/B-intoxications induced a similar course of disease both in terms of time to symptoms and time to death. Nevertheless, in agreement with the reported data from human clinical cases, complete protection could be demonstrated only for type A botulism. This serotypic divergence in responsiveness to antitoxin treatment is discussed in relation to the similar pattern observed in human clinical cases. A potential mechanism of the phenomenon that stems from the differential catalytic efficiencies of BoNT serotypes along with distribution variances of neural receptors and intracellular components involved in the mechanism of action of botulinum toxins in vertebrates is suggested.

Results

Reduced minute volume is a cross-serotypic early symptom of botulism in rabbits.

The rabbit spirometry model was previously used to quantify early respiratory symptoms of type E botulism that then served as a clinical trigger to treat (Diamant et al., 2018). The goal of the current study was to evaluate anti-BoNT/A and BoNT/B antitoxin efficacy after the onset of respiratory botulism symptoms using the spirometry model. To this end, the toxicity of BoNT/A and BoNT/B in rabbits was first studied by the determination of intramuscular (IM) LD₅₀. One IM rabbit LD₅₀ (1 RbIMLD₅₀) of BoNT/A and BoNT/B was found to be equal to 4 and 5 mouse intraperitoneal LD₅₀ per kg (MslPLD₅₀/kg), respectively. To allow characterization of the respiration physiology in botulinum-intoxicated rabbits, animals were exposed to 4 RbIMLD₅₀ of BoNT/A or BoNT/B and spirometry parameters were monitored pre-and post-exposure. Values were determined individually for all tested rabbits as previously described (Diamant et al., 2018) and were scored according to time to symptoms (TTS), i.e., the time post-exposure at which a statistically significant deviation (mean minus 2 SD) from the pre-exposure limit had occurred. In accordance with the results obtained for BoNT/E, the earliest spirometry parameter deviation in both BoNT/A and BoNT/B-intoxicated rabbits was observed in the minute volume (MV) parameter (TTS of 41.9±1.3 and 40.6±1.1 h for BoNT/A and BoNT/B, respectively, Fig. 1). MV was also the most consistent parameter with relative standard deviation (RSD) values of 13% and 16% for BoNT/A and BoNT/B, respectively. Thus, the MV parameter was chosen to become the leading clinical symptom for investigating antitoxin efficacy in symptomatic rabbits for both toxin serotypes. As with TTS, examination of time to death (TTD) after BoNT/A and BoNT/B exposure revealed comparable values (71.3±3.1 and 66.3±1.7 h, respectively) (Fig. 1). Thus, considering the similarity of TTS average values, both toxins induced a comparable course of disease.

Administration of antitoxin after the onset of respiratory symptoms fully protects BoNT/A but not BoNT/B intoxicated rabbits

To evaluate antitoxin efficacy in a clinically relevant fashion, spirometry was monitored before and after the administration of 4 RbIMLD₅₀ of BoNT/A or BoNT/B to groups of 12–15 rabbits. Rabbits were treated intravenously (IV) with 215 IU/kg of antitoxin A or B immediately after the onset of spirometry symptoms (Fig. 2). As shown in Fig. 2, symptom onset after BoNT/A or BoNT/B exposure ranged similarly (TTS of 32–51 and 32–45 h, respectively). Nevertheless, their immediate post-symptom treatment outcome was essentially different. BoNT/A antitoxin therapy given immediately after symptom onset was fully protective, as all treated rabbits survived (12/12), even when symptom onset was measured as late as 51 h. Moreover, rabbits (n=2) injected with an elevated BoNT/A dose (8 RbIMLD₅₀) and treated with the same dose of antitoxin immediately after symptom onset were also fully protected. In all treated rabbits, MV gradually returned to normal values and full respiration recovery was retained. In contrast to the results obtained with BoNT/A, PSAE in rabbits intoxicated with BoNT/B was limited and of a time-dependent nature. While all rabbits treated with antitoxin up to 36 h post exposure were fully protected by BoNT/B-antitoxin, no protection was observed when treatment was administered beyond this time point (Fig. 2). Notably, TTD of antitoxin treated rabbits (86.3 ± 9.7 h, Fig. 2) was significantly prolonged compared to that of negative control (toxin only) rabbits (66.3 ± 1.7 h, Fig. 1, $P=0.03$).

To further establish the time dependent PSAE observed in BoNT/B intoxicated rabbits, an additional set of 8 rabbits were exposed to 4 RbIMLD₅₀ of BoNT/B and were divided into 4 pairs according to post-exposure time treatment. Each pair was treated with BoNT/B antitoxin, regardless of the time of symptom onset, at the following post-exposure time intervals: 30, 33, 36 and 39 h. All rabbits treated before and up to 36 hours post-exposure were protected whereas 1 out of 2 rabbits treated at 39 h survived (Table 1). Notably, the rabbit that succumbed to the toxin did not show a significant spirometry symptom up until the time of antitoxin administration, supporting the view of a time course related antitoxin efficacy. The survival of one rabbit at 39 h may be due to normal animal variance. Nevertheless, together with the 10 non-surviving

treated rabbits in the experiment presented in Fig. 2, the beneficial response of antitoxin treatment given after 36 h of BoNT/B intoxication was less than 10%.

Positive and significant correlation between TTS and TTD in BoNT/A but not in BoNT/B intoxicated rabbits

In our previous study, a positive and statically significant correlation between TTS and TTD was found in BoNT/E-intoxicated rabbits, and all animals treated with antitoxin immediately following symptom onset survived (Diamant et al., 2018). In an attempt to determine whether the differential outcome of post-symptom antitoxin treatment in BoNT/A and BoNT/B intoxicated animals is related to TTS-TTD association, the correlation between these two parameters was analyzed for each of the two toxins. Evidently, a dramatic and significantly different pattern of correlation results were observed. While the TTD-TTS correlation was positive and statistically significant for BoNT/A ($r=0.91$, $P=0.0006$, Fig. 3A), a low and insignificant correlation was found for BoNT/B ($r=0.06$, $P=0.88$, Fig. 3B).

Efficacy of delayed post-symptom antitoxin treatment in BoNT/A intoxicated rabbits

Clinical diagnosis of botulism in human patients usually takes days to be completed (Hellmich et al., 2018). This further delays the administration of antitoxin to patients who are symptomatic in the first place upon arrival at the clinic. Therefore, we aimed to define the therapeutic time window for effective post-symptom antitoxin treatment in our system. To this end, antitoxin was administered to BoNT/A intoxicated rabbits two or five hours post-symptom onset and their survival was monitored (Fig. 4). The control rabbit ($n=1$) that received antitoxin immediately after the onset of the respiratory symptoms survived the 4 RbIMLD₅₀ BoNT/A intoxication (Fig. 4). Likewise, all rabbits ($n=3$) survived when antitoxin treatment was given two hours post-symptom onset (Fig. 4). However, further delaying the treatment to five hours post-symptom onset resulted in a lack of protection ($n=3$). These data emphasize how tightly the respiration symptoms are related to the clinical course of type A botulism in our model. Immediate antitoxin treatment provided full protection even when symptom onset was the latest to be observed (TTS=41, Fig. 4) or as late as 51

h (Fig. 2), while 5-hour post symptoms delayed treatment was ineffective even when symptoms appeared as early as 31 h. This observation clearly validates the relevance of the respiration symptoms as an adequate clinical symptom in relation to botulism A disease in rabbits.

Discussion

In most of the reported botulism animal studies aiming at evaluating post-exposure treatment efficacy, antitoxin was administered in a time post exposure mode. Only a few attempts have been made to study PSAE (Adler and Franz, 2016; Dack and Wood, 1928; Kodihalli et al., 2017; Oberst et al., 1968; Food and Drug Administration BAT[®] Data Sheet, <https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm345147.pdf>). Moreover, symptoms in these studies were limited to those that can only be noticed by simple observation. Notably, the detection of observed symptoms in animals is subjective and can be difficult to determine. In addition, while human patients report early botulism symptoms such as blurred vision, dry mouth and diplopia or just odd feelings long before the appearance of observable signs such as ptosis and difficulty in speaking (Mottate et al., 2016), animals, especially rodents, do not present such facial symptoms and obviously cannot report their situation (Hellmich et al., 2018). Therefore, observed early symptoms in animals may be considered as appearing at a later stage of the disease than early symptoms in humans. Altogether, this may explain, at least partially, the reason for the limited success of PSAE studies in animal models to date.

In the current study, we have used an objective and quantitative respiratory symptom to evaluate antitoxin efficacy in symptomatic rabbits. Symptom onset in this system appeared earlier than any visible symptom detectable by the naked eye. The validity of this system for early diagnosis of botulism was recently established by demonstrating full protection of symptomatic rabbits previously exposed to a lethal dose of BoNT/E, the fastest acting toxin of all BoNT serotypes. Several respiratory parameters were screened in the search for an optimal symptom for botulism during the establishment of the spirometry

model. Altogether, the data collected in our previous study and in the current study showed that the MV parameter presents the lowest variance and is the earliest to appear in rabbits exposed to all three botulinum serotypes that are responsible for > 99% of human cases of botulism (Diamant et al., 2018).

Rabbits exposed to BoNT/A or BoNT/B presented a similar course of disease in terms of TTS and TTD (Fig. 1). Moreover, the toxicity values measured for both serotypes were almost identical. In a previous study, we found that TTS and TTD were significantly shorter in rabbits exposed to an even lower lethal dose of BoNT/E (Diamant et al., 2018). This serotypic divergence in the dynamic of the disease was reported previously (Wang et al., 2008), (Woodruff et al., 1992). Indeed, individuals who were exposed to BoNT/E in food were admitted to hospital as early as 24 hours after ingestion of contaminated food, whereas in cases of type A botulism, the average time for hospitalization may vary up to 7 days post-exposure (Woodruff et al., 1992).

In the current study, all rabbits exposed to a lethal dose of BoNT/A (4 IMRLD₅₀) and treated with a human dose (body weight normalized) of antitoxin after the onset of botulism symptoms survived. Previous studies of PSAE in BoNT/A intoxicated animals showed mostly limited efficacy (Adler and Franz, 2016; Kodihalli et al., 2017; Food and Drug Administration BAT[®] Data Sheet, <https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm345147.pdf>). Adler and Franz reported on the efficacy of equine F(ab')₂ antitoxin administered either 24 hours post-exposure or after the onset of observed symptoms in non-human primates exposed to a lethal dose of inhalational BoNT/A (36 LD₅₀). While all animals (4/4) treated with 14 IU/kg of antitoxin 24 h post exposure survived, no survival (0/4) was recorded when antitoxin was administered after the onset of first signs of intoxication, even at a dose as high as 429 IU/kg (Adler and Franz, 2016). In a more recent rhesus macaque study, treatment with equine heptavalent antitoxin after the onset of clinical signs following an intravenous exposure to BoNT/A (1.7 LD₅₀) conferred only partial protection (46% survival) (Kodihalli et al., 2017). In small rodents, a higher PSAE was reported (Mimran et al., 2012; U.S. Food and Drug Administration BAT[®] Data Sheet,

<https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm345147.pdf>). The considerably improved antitoxin efficacy obtained using the rabbit spirometry system in the current study may be attributed to its sensitivity and to the quantitative and objective nature of the spirometry symptoms that appeared hours before any visible sign of intoxication could be observed.

Despite having very similar TTS and TTD values, post symptom antitoxin efficacy dramatically differed between BoNT/A and BoNT/B intoxicated rabbits. While PSAE was fully protective in BoNT/A intoxicated animals, only partial protection was obtained in rabbits exposed to BoNT/B. This serotypic divergence in PSAE closely co-aligned with the efficacy pattern observed in humans as recently reported in a meta-analysis of antitoxin efficacy in foodborne botulism cases covering nearly a century (O'Horo et al., 2017). The study concluded that a significant reduction in botulism-related mortality is associated with the use of type-E and type-A but not with type-B antitoxin. The ability to monitor individual TTS and TTD in our study in a highly controlled experiment demonstrated that PSAE is tightly associated with the correlation between these two fundamental characteristics of the disease. A high PSAE was associated with a positive and statistically significant correlation between TTS and TTD (type-A and type-E botulism), whereas poor PSAE was associated with a lack of correlation between these two parameters (type-B botulism).

The poor PSAE observed exclusively in BoNT/B intoxicated rabbits suggests that at the time of symptom onset a lethal dose of BoNT/B has already entered the neurons, while considerable amounts of BoNT/A and BoNT/E were still circulating and available for neutralization. Such a phenomenon could occur in cases of differences in the endopeptidase catalytic efficiencies of BoNT serotypes. Indeed, Barbieri and colleagues have shown that the catalytic constant (k_{cat}) of LC/A and LC/E found for recombinant, soluble and membrane-free substrates are 60 and 77 s^{-1} , respectively, while that of LC/B is 1.08 s^{-1} (Chen and Barbieri, 2009; Chen et al., 2008; Chen et al., 2007). In addition, the catalytic efficiency (k_{cat}/K_M) of LC/B was shown to be an order of magnitude lower than that of LC/A and two orders of magnitude lower than that of LC/E

(0.67, 3.7, and 50 s⁻¹μM⁻¹, respectively). Thus, if the BoNT/B catalytic activity is significantly slower than that of BoNT/A and BoNT/E, the interval between cell entrance and neuron paralysis is prolonged, and more BoNT/B molecules may intoxicate additional neurons before symptom onset. The similar TTS we observed in BoNT/A and BoNT/B intoxicated rabbits, may suggest that slower catalytic activity of BoNT/B was compensated by a faster binding and internalization. In this case, it is reasonable to assume that at the time of symptom onset a significantly lower amount of BoNT/B was available in the circulation for neutralization by antitoxin and a lethal dose had already entered the neurons.

It should be noted that besides the catalytic efficiency property, differences in the binding and catalytic target molecules of these BoNT serotypes may also contribute to the differential PSAE. Both BoNT/A and BoNT/E share common molecular characteristics that differ from those of BoNT/B. BoNT/A and BoNT/E bind the SV2 receptor on neural cells whereas BoNT/B binds synaptotagmin (Syt) I and II. Moreover, BoNT/B differs from BoNT/A and BoNT/E in the SNARE target protein that is cleaved within the neural cells. BoNT/A and BoNT/E cleave the 25 kDa synaptosomal associated protein (SNAP-25), while BoNT/B cleaves the vesicle-associated membrane protein (VAMP) (Arsenault et al., 2014; Binz et al., 1994; Kalandakanond and Coffield, 2001; Osen-Sand et al., 1996; Rhee et al., 1997; Schiavo et al., 1994; Schiavo et al., 1993a; Schiavo et al., 1993b; Washbourne et al., 1997; Yadirgi et al., 2017; Yamamoto et al., 2012). In addition, diversification in the presence, amounts, affinity, distribution and function of these receptors and SNARE proteins in the target tissues (Fox and Sanes, 2007; Peng et al., 2014) should also be considered as potential contributors to the differential PSAE after BoNT/B vs. BoNT/A and BoNT/E intoxication.

In conclusion, the rabbit spirometry system was applied in the current work to study the efficacy of antitoxin, the only approved therapy against botulism, using the relevant trigger to treat in humans, i.e., post symptom manifestation. The similar serotypic pattern of PSAE obtained in the current study and its correlation with reported human cases may emphasize the validity of the rabbit spirometry system and its superiority over other small animal models .

Moreover, in respect to the animal rule (Food and Drug Administration <https://www.fda.gov/downloads/drugs/guidances/ucm399217.pdf>), the serotypic divergence found in the current study suggests that a certain trigger to treat may not necessarily be valid for all BoNT serotypes in a given animal model. The rabbit spirometry system should be considered as a potential component in the evaluation toolkit of new therapeutics, including drugs intended to act intracellularly at later stages of botulism where antitoxin is no longer effective.

MATERIALS AND METHODS

Ethics statement

All animal experiments were performed in accordance with Israeli law and were approved by the Ethics Committee for animal experiments at the Israel Institute for Biological Research (protocols # RB-18-11, RB-24-11, RB-28-11, RB-12-12 and RB-14-12). All efforts were made to minimize suffering.

Bacteria and toxins

Clostridium botulinum A and B strains were obtained from the Israel Institute for Biological Research (IIBR) collection (A198 and B592, respectively). A sequence analysis revealed compliance of the neurotoxin genes with serotypes 62A (GenBank Accession Number M30196) and Danish (GenBank Accession Number M81186) of *C. botulinum* types A1 and B1, respectively (Binz et al., 1990; Whelan et al., 1992). Toxin complexes were prepared from concentrated supernatants of cultures grown for 6 days in anaerobic culture tubes. The specific activity of the toxin preparations was determined to be 7.4×10^6 MsLD₅₀/mg and 1.5×10^7 MsLD₅₀/mg for BoNT/A and BoNT/B, respectively. Toxin stock was kept in 50 mM citrate buffer (pH = 5.5) at -70°C . For determination of the lethal dose (mouse lethality assay), serial dilutions of the toxin in gelatin buffer (0.2% w/v gelatin in phosphate buffer, pH = 6.4) were injected intraperitoneally into groups of mice (n = 5) as described by Malizio et al. (Malizio et al., 2000) and lethality was calculated according to Spearman–Karber method (Irwin and Cheeseman, 1939).

Antitoxin

Horse anti-BoNT/A or anti-BoNT/B plasma were collected from hyper-immune animals immunized with toxoid prepared by dialyzing the toxin complex against 0.14% formalin at 35°C for 2 weeks (Diamant et al., 2014). The Fc fragment was removed by pepsin digestion (Torgeman et al., 2017) and purified F(ab)² antitoxin neutralizing activity was determined according to the European Pharmacopeia (European Directorate for the Quality of Medicines and Healthcare, 2014). Briefly, serial 1.2-fold dilutions of each antitoxin preparation were prepared. Simultaneously, a standard antitoxin preparation (calibrated according to the World Health Organization international standard antitoxin) was diluted to the final concentrations of 0.08, 0.10, 0.12, 0.14 International Units per mL (IU/mL). All antitoxin dilutions were then mixed with a fixed toxin test dose, and the mixtures were incubated for 1 h at 25 °C. Each mixture was injected intraperitoneally into four mice (CD-1; Charles River UK) (1 mL per mouse), and survival was monitored for four days. Antitoxin potency was calculated based on the lowest dilution of antitoxin that failed to protect the animals when compared to that of the standard antitoxin.

Spirometry system

Inhalation parameters were recorded by a computer-monitored spirometry system. The system consisted of a snout-only mask connected to a T type non-rebreathing two-way valve. A model 4100 Thermal Mass Flowmeter (TSI Inc., Shoreview, MN USA) with low flow resistance was connected to the inhalation port of the valve. During measurements, non-anesthetized rabbits respired freely. The data collected from naïve animals were in line with published values of normal rabbit respiration physiology (Bide et al., 2000).

Inhalation data were collected at 20-millisecond intervals (500 data points in 10 seconds). Each rabbit measurement lasted up to 2 minutes. Spirometry parameters that included minute volume, rate, and tidal volume were measured and data were analyzed with Microsoft Excel (2013). Based on preliminary experiments, rabbit spirometry measurements conducted in intervals not shorter than 2 hours did not affect spirometry performance. Accordingly, at least 12 independent measurements collected over 7 days (up to twice a day) were used to calculate the individual mean and standard deviation (SD) of each one

of the three spirometry parameters. Confidence limits were determined as the mean \pm 2 SD (Diamant et al., 2018). Values below the lower limit in BoNT-exposed rabbits were attributed to breathing distress due to the intoxication and thus were considered as clinical symptoms of botulism.

Antitoxin efficacy studies

Naïve rabbits, previously monitored for individual respiration performance, were injected in the quadriceps musculature of the hind limb with 4 rabbit intramuscular (IM) lethal dose fifty (4 RbIMLD₅₀) of BoNT/A or BoNT/B in 0.5 ml of gelatin-phosphate buffer (50 mM Na-phosphate, 0.2% gelatin, pH=6.5). Where indicated, BoNT/A was tested with 8 RbIMLD₅₀. Rabbit spirometry was monitored starting at 24 hours post-intoxication and then at 2–24 hours intervals. An animal that presented a significant deviation from its pre-intoxication respiration performance (lower than the mean value minus 2 standard deviations) was defined as symptomatic. Antitoxin was intravenously administered to symptomatic rabbits at the indicated time post-symptom onset. The antitoxin dose was the equivalent in body weight to the human indicated dose (215 IU/kg). All experiments included negative control (toxin only) rabbits.

ACKNOWLEDGEMENTS

This work was supported by the Israel Institute for Biological Research (grant number SB-62).

Competing interests

No competing interests declared

REFERENCES

Adler, M. and Franz, D. R. (2016). Toxicity of botulinum neurotoxin by inhalation: implications in bioterrorism. In *Aerobiology: The Toxicology of Airborne Pathogens and Toxins*, (ed. H. Salem and S. Katz), pp. 167–185. Cambridge, United Kingdom: The Royal Society of Chemistry.

Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M. et al. (2001). Botulinum toxin as a biological weapon: Medical and public health management. *JAMA* **285**, 1059-1070.

Arsenault, J., Cuijpers, S. A., Ferrari, E., Niranjana, D., Rust, A., Leese, C., O'Brien, J. A., Binz, T. and Davletov, B. (2014). Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells. *J. Neurochem.* **129**, 781-791.

Bide, R. W., Armour, S. J. and Yee, E. (2000). Allometric respiration/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. *J. Appl. Toxicol.* **20**, 273-290.

Binz, T., Blasi, J., Yamasaki, S., Baumeister, A., Link, E., Sudhof, T. C., Jahn, R. and Niemann, H. (1994). Proteolysis of SNAP-25 by types E and A botulinum neurotoxins. *J. Biol. Chem.* **269**, 1617-1620.

Binz, T., Kurazono, H., Wille, M., Frevert, J., Wernars, K. and Niemann, H. (1990). The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. *J. Biol. Chem.* **265**, 9153-9158.

Centers for Disease Control and Prevention (CDC). (2010). Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. *Morb. Mortal. Wkly. Rep.* **59**, 299.

Chen, S. and Barbieri, J. T. (2009). Engineering botulinum neurotoxin to extend therapeutic intervention. *Proc. Natl. Acad. Sci. U S A.* **106**, 9180-4.

Chen, S., Hall, C. and Barbieri, J. T. (2008). Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. *J. Biol. Chem.* **283**, 21153-21159.

Chen, S., Kim, J. J. and Barbieri, J. T. (2007). Mechanism of substrate recognition by botulinum neurotoxin serotype A. *J. Biol. Chem.* **282**, 9621-9627.

Dack, G. M. and Wood, W. L. (1928). Serum therapy of botulism in monkeys. *The J. of. Infect. Dis.* **42**, 209-212.

Dembek, Z. F., Smith, L. A. and Rusnak, J. M. (2007). Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. *Disaster Med. Public. Health. Prep.* **1**, 122-134.

Diamant, E., Lachmi, B. E., Keren, A., Barnea, A., Marcus, H., Cohen, S., David, A. B. and Zichel, R. (2014). Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. *PLoS One* **9**, e87089.

Diamant, E., Pass, A., Rosen, O., Ben David, A., Torgeman, A., Barnea, A., Tal, A., Rosner, A. and Zichel, R. (2018). A Novel Rabbit Spirometry Model of Type E Botulism and its Use for the Evaluation of Post-symptom Antitoxin Efficacy. *Antimicrob. Agents. Chemother.* **62**, e02379-17.

European Directorate for the Quality of Medicines and Healthcare. (2014). Botulinum antitoxin. In *European pharmacopoeia*, vol. 1, pp. 1029. Strasbourg, France: EDQM Council of Europe.

Fox, M. A. and Sanes, J. R. (2007). Synaptotagmin I and II are present in distinct subsets of central synapses. *J. Comp. Neurol.* **503**, 280-296.

Franz, D. R., Pitt, L. M., Clayton, M. A., Hanes, M. A. and Rose, K. J. (1993). Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In *Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects*, (ed. B. R. Das-Gupta), pp. 473-476. New York, NY: Plenum Press.

Habermann, E. and Bernath, S. (1975). Preparation, measurement and possible use of human antitoxin against Cl. botulinum A, B, and E toxins. *Med. Microbiol. Immunol.* **161**, 203-210.

Hellmich, D., Wartenberg, K. E., Zierz, S. and Mueller, T. J. (2018). Foodborne botulism due to ingestion of home-canned green beans: two case reports. *J. Med. Case. Rep.* **12**, 1

Iida, H., Ono, T. and Karashimada, T. (1970a). Experimental studies on the serum therapy of type E botulism: the relationship between the amount of toxin in the blood and the effect of antitoxic serum. *Jpn. J. Med. Sci. Biol.* **23**, 344-347.

Iida, H., Ono, T., Karashimada, T. and Ando, Y. (1970b). Studies on the serum therapy of type E botulism: absorption of toxin from the gastrointestinal tract. *Jpn. J. Med. Sci. Biol.* **23**, 282-285.

Irwin, J. O. and Cheeseman, E. A. (1939). On an approximate method of determining the median effective dose and its error, in the case of a quantal response. *J. Hyg. (Lond)* **39**, 574-580.

Johnson, E. A. and Montecucco, C. (2008). Botulism. *Handb. Clin. Neurol.* **91**, 333-368.

Kalandakanond, S. and Coffield, J. A. (2001). Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue. *J. Pharmacol. Exp. Ther.* **296**, 749-755.

Kodihalli, S., Emanuel, A., Takla, T., Hua, Y., Hobbs, C., LeClaire, R. and O'Donnell, D. C. (2017). Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques. *PLoS One* **12**, e0186892.

Kongsaengdao, S., Samintarapanya, K., Rusmeechan, S., Wongs, A., Pothirat, C., Permpikul, C., Pongpakdee, S., Puavilai, W., Kateruttanakul, P., Phengtham, U. et al. (2006). An outbreak of botulism in Thailand: Clinical manifestations and management of severe respiratory failure. *Clin. Infect. Dis.* **43**, 1247-1256.

Lewis Jr, G. E. and Metzger, J. F. (1979). Studies on the prophylaxis and treatment of botulism. *Toxicon* **17**, 102.

Malizio, C. J., Goodnough, M. C. and Johnson, E. A. (2000). Purification of Clostridium botulinum type A neurotoxin. *Methods. Mol. Biol.* **145**, 27-39.

McCarty, C. L., Angelo, K., Beer, K. D., Cibulskas-White, K., Quinn, K., de Fijter, S., Bokanyi, R., St Germain, E., Baransi, K., Barlow, K. et al. (2015). Large Outbreak of Botulism Associated with a Church Potluck Meal--Ohio, 2015. *Morb. Mortal. Wkly. Rep.* **64**, 802-803.

Mimran, A., Chay, Y., Barnea, A., Halperin, G., Reuveny, S. and Zichel, R. (2012). Evaluating the efficacy of post-clinical symptom anti-toxin therapy in a mouse model of botulism A and B. In *49th Interagency Botulism Research Coordinating Committee (IBRCC)*. Baltimore, MD, USA.

Mottate, K., Yokote, H., Mori, S., Horita, A., Miyatsu, Y., Torii, Y., Kozaki, S., Iwaki, M., Takahashi, M. and Ginnaga, A. (2016). Retrospective

survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan. *Toxicon* **110**, 12-18.

O'Horo, J. C., Harper, E. P., El Rafei, A., Ali, R., DeSimone, D. C., Sakusic, A., Abu Saleh, O. M., Marcelin, J. R., Tan, E. M., Rao, A. K. et al. (2017). Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016. *Clin. Infect. Dis.* **66**, S43-s56.

Oberst, F. W., Crook, J. W., Cresthull, P. and House, M. J. (1968). Evaluation of botulinum antitoxin, supportive therapy, and artificial respiration in monkeys with experimental botulism. *Clin. Pharmacol. Ther.* **9**, 209-214.

Ono, T., Karashimada, T. and Iida, H. (1969). Studies on the serum therapy of type E botulism. II. *J. Infect. Dis.* **120**, 534-538.

Ono, T., Karashimada, T. and Iida, H. (1970). Studies of the serum therapy of type E botulism. 3. *Jpn. J. Med. Sci. Biol.* **23**, 177-191.

Osen-Sand, A., Staple, J. K., Naldi, E., Schiavo, G., Rossetto, O., Petitpierre, S., Malgaroli, A., Montecucco, C. and Catsicas, S. (1996). Common and distinct fusion proteins in axonal growth and transmitter release. *J. Comp. Neurol.* **367**, 222-234.

Peng, L., Adler, M., Demogines, A., Borrell, A., Liu, H., Tao, L., Tepp, W. H., Zhang, S. C., Johnson, E. A., Sawyer, S. L. et al. (2014). Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins. *PLoS Pathog.* **10**, e1004177.

Pirazzini, M., Rossetto, O., Eleopra, R. and Montecucco, C. (2017). Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. *Pharmacol. Rev.* **69**, 200-235.

Rhee, S. D., Jung, H. H., Yang, G. H., Moon, Y. S. and Yang, K. H. (1997). Cleavage of the synaptobrevin/vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin. *FEMS Microbiol. Lett.* **150**, 203-208.

Rossetto, O., Pirazzini, M. and Montecucco, C. (2014). Botulinum neurotoxins: genetic, structural and mechanistic insights. *Nat. Rev. Microbiol.* **12**, 535-549.

Schiavo, G., Rossetto, O., Benfenati, F., Poulain, B. and Montecucco, C. (1994). Tetanus and botulinum neurotoxins are zinc proteases

specific for components of the neuroexocytosis apparatus. *Ann. NY Acad. Sci.* **710**, 65-75.

Schiavo, G., Rossetto, O., Catsicas, S., Polverino de Laureto, P., DasGupta, B. R., Benfenati, F. and Montecucco, C. (1993a). Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. *J. Biol. Chem.* **268**, 23784-23787.

Schiavo, G., Santucci, A., Dasgupta, B. R., Mehta, P. P., Jontes, J., Benfenati, F., Wilson, M. C. and Montecucco, C. (1993b). Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. *FEBS Lett.* **335**, 99-103.

Sobel, J. (2005). Botulism. *Clin. Infect. Dis.* **41**, 1167-73.

Sugiyama, H. (1980). *Clostridium botulinum* neurotoxin. *Microbiol. Rev.* **44**.

Tacket, C. O., Shandera, W. X., Mann, J. M., Hargrett, N. T. and Blake, P. A. (1984). Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. *Am. J. Med.* **76**, 794-798.

Torgeman, A., Mador, N., Dorozko, M., Lifshitz, A., Eschar, N., White, M. D., Wolf, D. G. and Epstein, E. (2017). Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion. *Biologicals* **48**, 24-27.

Wang, J., Meng, J., Lawrence, G. W., Zurawski, T. H., Sasse, A., Bodeker, M. O., Gilmore, M. A., Fernandez-Salas, E., Francis, J., Steward, L. E. et al. (2008). Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. *J. Biol. Chem.* **283**, 16993-7002.

Washbourne, P., Pellizzari, R., Baldini, G., Wilson, M. C. and Montecucco, C. (1997). Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. *FEBS Lett.* **418**, 1-5.

Weber, J. T., Hibbs Jr, R. G., Darwish, A., Mishu, B., Corwin, A. L., Rakha, M., Hatheway, C. L., El Sharkawy, S., El-Rahim, S. A., Al-Hamd, M. F. S. et al. (1993). A massive outbreak of type E botulism associated with traditional salted fish in Cairo. *J. Infect. Dis.* **167**, 451-454.

Whelan, S. M., Elmore, M. J., Bodsworth, N. J., Atkinson, T. and Minton, N. P. (1992). The complete amino acid sequence of the *Clostridium*

botulinum type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene. *Eur. J. Biochem.* **204**, 657-667.

Woodruff, B. A., Griffin, P. M., McCroskey, L. M., Smart, J. F., Wainwright, R. B., Bryant, R. G., Hutwagner, L. C. and Hatheway, C. L. (1992). Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. *J. Infect. Dis.* **166**, 1281-1286.

Yadirgi, G., Stickings, P., Rajagopal, S., Liu, Y. and Sesardic, D. (2017). Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency. *J. Immunol. Methods* **451**, 90-99.

Yamamoto, H., Ida, T., Tsutsuki, H., Mori, M., Matsumoto, T., Kohda, T., Mukamoto, M., Goshima, N., Kozaki, S. and Ihara, H. (2012). Specificity of botulinum protease for human VAMP family proteins. *Microbiol. Immunol.* **56**, 245-253.

Figures




Fig. 1. Comparable course of disease in BoNT/A and BoNT/B intoxicated rabbits. Rabbits were exposed to 4 RbIMLD₅₀ of BoNT/A or BoNT/B and the time from intoxication to symptom onset and death was individually determined. Time to symptoms (TTS) was determined for each rabbit based on the minute volume (MV) parameter. Note: TTS data were collected both from negative control (toxin only) and from antitoxin-treated rabbits. The TTD data are from toxicity experiments. Data represents mean±SEM.




Fig. 2. Post symptom antitoxin treatment is fully protective in BoNT/A, but not in BoNT/B intoxicated rabbits. Rabbits were exposed to 4 RbIMLD₅₀ of BoNT/A or BoNT/B, and antitoxin (215 IU/kg) was administered IV immediately after the onset of spirometry symptoms. Each plotted symbol ("o"=survival; "x"=death) refers to an individual animal. Dashed line represents the latest time point (36 h) at which symptomatic rabbits were fully protected by antitoxin treatment. Data were collected from at least three independent experiments. Each experiment included negative control (toxin only) rabbits. TTS values of accompanying negative control (toxin only) rabbits (n=8, 42.25±1.19 and 41.75±1.32 h for BoNT/A and BoNT/B, respectively) were comparable to those of antitoxin treated rabbits.




Fig. 3. Correlation analysis between TTD and TTS in rabbits intoxicated with a lethal dose of BoNT/A or BoNT/B. Rabbits were exposed to 4 RbIMLD₅₀ of BoNT/A (A panel) or BoNT/B (B panel) and the correlation between TTD and TTS was analyzed (correlation is based on negative control (toxin only) data presented in Fig. 1).




Fig. 4. Delayed antitoxin treatment following botulism A symptom onset. Rabbits were intoxicated with 4 RbIMLD₅₀ of BoNT/A and treated with 215 IU/kg of antitoxin immediately (0), 2, or 5 hours post symptom onset. Each plotted symbol ("o" =survival; "x"=death) refers to an individual animal. The TTS of the accompanying negative control (toxin only) rabbit (n=1) was 36 h.

Table

Table 1. Time course antitoxin efficacy in BoNT/B intoxicated rabbits.

Time to treatment [h]	No. of surviving rabbits/no. of treated rabbits*
Control**	0/1
30	2/2
33	2/2
36	2/2
39	1/2

* Four pairs of rabbits were exposed to 4 RbIMLD₅₀ of BoNT/B and treated with antitoxin (215 IU/kg) at the indicated time post-intoxication. ** Negative control (toxin only) rabbit.